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Abstract 
Various fusion tags are commonly employed to increase the heterologous expression and solubility of 
aggregation-prone proteins within Escherichia coli. Herein, we present a protocol for efficient recombinant 
expression and purification of the human RNA demethylases Alkbh5 and FTO. Our method incorporates a 
novel fusion tag (the N-terminal domain of bacterial enzyme I, EIN) that dramatically increases the 
solubility of its fusion partner and is promptly removed upon digestion with a protease. The presented 
protocol allows for the production of mg amounts of Alkbh5 and FTO in 1L of both rich and minimal 
media. We developed a liquid chromatography-mass spectrometry (LC-MS)-based assay to confirm that 
both proteins are enzymatically active. Furthermore, the LC-MS method developed here is applicable to 
other members of the AlkB family of Fe(II)/α-ketoglutarate-dependent dioxygenases. The superior protein 
yield, afforded by our expression and purification method, will facilitate biochemical investigations into 
the biological function of the human RNA demethylases and endorse employment of EIN as a broadly 
applicable fusion tag for recombinant expression projects. 
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Abstract 
Various fusion tags are commonly employed to increase the heterologous expression and 
solubility of aggregation-prone proteins within Escherichia coli. Herein, we present a protocol for 
efficient recombinant expression and purification of the human RNA demethylases Alkbh5 and 
FTO. Our method incorporates a novel fusion tag (the N-terminal domain of bacterial enzyme I, 
EIN) that dramatically increases the solubility of its fusion partner and is promptly removed upon 
digestion with a protease. The presented protocol allows for the production of mg amounts of 
Alkbh5 and FTO in 1L of both rich and minimal media. We developed a liquid chromatography-
mass spectrometry (LC-MS)-based assay to confirm that both proteins are enzymatically active. 
Furthermore, the LC-MS method developed here is applicable to other members of the AlkB 
family of Fe(II)/α-ketoglutarate-dependent dioxygenases. The superior protein yield, afforded by 
our expression and purification method, will facilitate biochemical investigations into the 
biological function of the human RNA demethylases and endorse employment of EIN as a 
broadly applicable fusion tag for recombinant expression projects. 
 
 
Keywords 
Enzyme I; gene fusion; solubility tag; recombinant expression; N6-methyladenosine 
  
3 
 
Introduction 
Recombinant expression of proteins in bacterial hosts has dramatically increased our 
ability to interrogate protein function at the molecular level. Indeed, such technology has allowed 
for expression and purification of a myriad of proteins in mg amounts. Furthermore, bacterial 
expression systems have facilitated sophisticated labeling schemes—both biomimetic and 
artificial—such as isotope labeling, site-specific modifications, and non-natural amino acid 
incorporation. However, several challenges, including low solubility of the target protein in the 
bacterial host, misfolding, and host cell toxicity, have hampered the use of the recombinant DNA 
technology in the production of several “hard to express” or unstable proteins. 
The use of fusion tags is a common practice for improving the expression and solubility 
of challenging systems.1-16 Fusion tags are proteins or peptides that are fused in-frame and 
expressed with the target protein, either for improving expression and solubility, or to aid in the 
purification of the target proteins. Common fusion proteins known to enhance solubility and 
expression include Maltose Binding Protein (MBP)1-2, Small Ubiquitin-related Modifier (SUMO)3-
4, Glutathione S-transferase (GST)5, N-utilization substance A (NusA),6 and B1 domain of 
Streptococcal protein G (GB1)7. Nevertheless, the discovery of new fusion tags is valuable as 
no single tag is capable of solving low expression and solubility issues for all target proteins.  
Herein, we show that the N-terminal domain of Escherichia coli Enzyme I (EIN) functions 
as novel fusion tag that substantially enhances recombinant expression and solubility of the 
human RNA demethylases Alkbh5 and FTO, two oncoproteins whose overexpression has been 
linked to the development of leukemia, breast, and brain cancer (note that crystal structures of 
the human Alkbh5 and FTO are reported as Supporting Information, Figure S1).17-19 In addition, 
we developed a new Liquid Chromatography-Mass Spectrometry (LC-MS) assay to confirm that 
the purified proteins are enzymatically active. Therefore, our results will facilitate future 
biochemical and structural investigations on the molecular mechanisms connecting the human 
RNA demethylases to the development of cancer. Interestingly, we also show that the EIN 
fusion tag presented here has a similar impact on recombinant expression of Alkbh5 and FTO 
as MBP but is cleaved off the target protein more efficiently than MBP. Based on this data, we 
anticipate that EIN can be used to improve the yield of other “hard to express” genes and can 
be added to the portfolio of the fusion tags routinely employed in protein expression and 
purification applications. 
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Materials and Methods 
Fusion plasmid construction and Recombinant expression in M9 minimal medium – All plasmids 
used in this work were constructed using pET21a (Novagen) as the backbone vector. Gibson 
assembly20 was used to incorporate the fusion genes and TEV cleavage site, which are 
described in Results. Plasmids were transformed into Escherichia coli BL21 Star (DE3) 
(Invitrogen), and transformants were selected on LB-agar containing ampicillin (100 µg/ml). 
Cells were grown at 37 °C in LB or M9 minimal medium. The composition of the LB medium 
(Pre-buffered LB capsule from Fisher Bioreagents) was as follows: 5.0 g/L Casein peptone, 5.0 
g/L Yeast extract, 5 g/L NaCl, and 1.5 g/L Tris-HCl (pH 7.2). The composition of the M9 minimal 
medium was as follows: 6.5 g/L Na2HPO4, 3 g/L KH2PO4, 0.5 g/L NaCl, 4 g/L Glucose, 1g/L 
NH4Cl, 100 mg/L ampicillin, 120 mg/L MgSO4, 11 mg/L CaCl2, and 10 mL/L of 100x MEM 
Vitamin mix (Gibco). At OD600nm ~ 0.6 the temperature was reduced to 16 °C, and expression 
was induced via addition of 1 mM isopropyl-D-thiogalactopyranoside (IPTG). Cells were 
harvested by centrifugation after 16 h of induction. 
Purification of Alkbh5 and FTO – Harvested cells were resuspended in 20 mL of 50 mM Tris-
HCl (pH 8.0) and 500 mM NaCl. The suspension was lysed using an EmulsiFlex-C3 
microfluidizer (Avestin) and subsequently centrifuged at 40,000 ×g for 40 min. The supernatant 
traversed a 0.45 µM filter and was loaded onto a HisTrap HP column (5 mL; GE Healthcare). 
The protein was eluted in 50 mM Tris-HCl (pH 8.0) and 500 mM NaCl using a 100 mL gradient 
from 0 mM to 375 mM Imidazole. The fractions containing the target protein were confirmed by 
SDS-polyacrylamide gel electrophoresis. The eluted protein was buffer exchanged into 50 mM 
Tris-HCl (pH 8.0) and 500 mM NaCl before being concentrated to 15 mL using an Amicon Ultra 
centrifugal filter (Millipore). The EIN or MBP tag was cleaved by incubation at room temperature 
with 0.25 mg of His-tagged Tobacco Etch Virus (TEV) protease. The TEV protease was 
expressed and purified in our lab. The same batch of protease was used throughout the entire 
work presented here. The length of incubation was optimized experimentally (see Results). After 
cleavage of the fusion tag, the protease and the liberated fusion tag was removed by a 
subtractive passage through the HisTrap HP column. The flow-through was concentrated and 
further purified on a Superdex-75 column (GE Healthcare) equilibrated with 20 mM Tris-HCl (pH 
7.4), 200 mM NaCl, 2 mM dithiothreitol (DTT), and 1 mM ethylenediaminetetraacetic acid 
(EDTA). Fractions containing the target protein were confirmed by SDS-polyacrylamide gel. 
Enzymatic assay – Enzymatic assays were performed in a final reaction volume of 300 µL. The 
reaction mixture consisted of 0.1 µM Alkbh5 or 2 µM FTO and varying substrate concentrations 
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(0.5, 1, 2, 3, 5, and 10 µM for Alkbh5 or 4, 8, 12, 20, and 40 µM for FTO) in the following 
reaction buffer: 2 mM L-ascorbic acid, 150 µM Fe (II), and 300 µM αKG in 50 mM Tris-HCl (pH 
7.4). The 5-mer substrate, 5’-GG(m6A)CT-3’, was chosen based on previous reports indicating 
that both Alkbh5 and FTO are active against this oligonucleotide.21 Reactions were incubated at 
37 °C. 50 µL aliquots were taken at regular time intervals (5, 10, 20, 30, 45, and 60 min for 
Alkbh5; 15, 30, 60, 120, and 240 min for FTO) and quenched with a 1:1 ratio of 20% (v/v) formic 
acid. The quenched reactions were passed through a 0.2 µm, 0.4 mL Ultrafree-MC Centrifugal 
Filter column (Millipore) by centrifugation (16,000 g for 5 min) to separate the enzyme from the 
nucleic acid. The pH of the flow-through, containing a mixture of the methylated and 
demethylated substrate, was neutralized by addition of HPLC grade NH4OH and analyzed by 
liquid chromatography – mass spectrometry (LC-MS). The LC-MS analysis was conducted 
using an Agilent Technologies 1290 Infinity Binary Pump UHPLC system coupled to an Agilent 
Technologies 6540 UHD Accurate-Mass Q-TOF mass spectrometer set to negative mode. The 
system was operated in high-resolution mode (4Gz) while scanning m/z 100-1700. The 
oligomers were separated on a ZORBAX Rapid Resolution HT Extended C18 column (80 Å, 1.8 
µm, 2.1 x 50 mm). UHPLC separations were performed using a column temperature of 40°C 
with a flow rate of 0.3 mL/min. The solvent gradient began at 100% solvent A (5 mM NH4OH in 
H2O) progressing with a gradient to 25% solvent B (5 mM NH4OH in 70% acetonitrile) for 7 min, 
increased to 100% solvent B at 10 min, and returned to starting conditions at 12 min. A 3 min 
post-run with initial conditions was applied after each acquisition. The Q-TOF was used to 
determine the composition and purity of the peaks observed in the UHPLC dimension by mass-
to-charge (m/z). The z = -2 species for both the methylated (m/z=757.533) and the 
demethylated (m/z=750.515) oligomers were predominately observed (see Results). The 
percent demethylation was calculated by the ratio of the integrated peak areas associated with 
each oligomer. 
 
Results and Discussion 
Overexpression of soluble Alkbh5 and FTO – Several of the structural and biochemical 
characterizations of Alkbh5 and FTO reported in the literature were conducted on truncated 
enzymes (residues 66-292 and residues 32-505 for Alkbh5 and FTO, respectively).22-29 These 
truncated constructs were selected to facilitate recombinant expression and crystallization of the 
RNA demethylases and were shown to retain full enzymatic activity.22-29 Here, the truncated 
constructs of Alkbh5 and FTO were cloned into a pET21a, transformed into E. coli BL21 Star 
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(DE3) competent cells, and expressed in Luria-Bertani (LB) or M9 minimal medium as described 
in Materials and Methods. Results reported in Figure 1 indicate that the two proteins are highly 
overexpressed but poorly soluble in E. coli. Indeed, overexpressed protein largely accumulates 
within inclusion bodies, despite the slow, low-temperature (16 °C), expression conditions (see 
Materials and Methods). The low solubility of the RNA demethylases obstructs analysis by high 
resolution techniques that require preparation of mg amounts of protein.  
To increase expression of soluble Alkbh5 and FTO, we explored the use of an N-
terminal solubility tag. Two different solubility tags were tested: the E. coli MBP (molecular 
weight: 40.7 kDa), and the E. coli EIN (molecular weight: 27 kDa). While MBP is one of the 
frequently implemented solubility tags for recombinant expression in E. coli30-32, EIN has not 
been employed in gene fusion applications yet. We opted to test EIN as a solubility tag because 
we have worked with this protein for several years33-42 and have noticed that (i) EIN is a well-
folded protein with high thermodynamic stability (melting temperature ~ 55 °C), (ii) EIN is highly 
expressed (> 100 mg per L of culture) as a soluble protein in E. coli, and (iii) EIN is sufficient to 
recover overexpression and solubility of mutations of the EI C-terminus (EIC) that destabilize 
the EIC fold.  
To test the capacity of an EIN-fusion to promote solubility, two constructs were designed 
in which the target protein (Alkbh5 or FTO) is fused to an N-terminal MBP or EIN tag. To 
facilitate purification of the target protein, the two constructs also included an N-terminal His-tag, 
and the TEV protease consensus sequence (ENLYFQ/S, where “/” signifies the cleaved peptide 
bond) was positioned between the solubility tag and the target protein. Further, the Nde I 
recognition sequence was used as a spacer between the TEV protease cleavage site and the 
target gene to facilitate TEV access to the cleavage site and expedite future cloning efforts. The 
synthesized constructs were cloned into a pET21a vector between the Xba I and BamH I 
restriction sites, and the resulting plasmid map is shown in Figure 2. The data reported in Figure 
1 indicates that both the MBP and EIN tags have a similar impact on the expression of Alkbh5 
and FTO, which significantly enhances the solubility of both RNA demethylases. 
Purification of enzymatically active Alkbh5 and FTO – Purification of the target protein from the 
cell lysate was carried out using a four-step protocol (for details, see “Materials and Methods”). 
Briefly, a first His-tag purification step was used to isolate the target protein from most protein 
and nucleic acid contaminants (step 1). The fused construct was then incubated with 15 μg/mL 
of TEV protease to cleave the solubility tag away from the RNA demethylases (step 2). A 
second His-tag purification step was performed to separate the solubility tag and the protease 
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(which incorporate an N-terminal His tag) from the target enzyme (step 3), and a final gel 
filtration step was added to eliminate any residual contamination (step 4). The final enzyme 
yields for both Alkbh5 and FTO were > 90% pure, as determined by SDS-PAGE (Figure 3a). It 
is worth noticing that the two RNA demethylases show a higher apparent molecular weight by 
SDS-PAGE than expected based on the amino acid sequence (26,375 Da and 54,810 Da for 
Alkbh5 and FTO, respectively). Higher apparent molecular weight in SDS-PAGE gels are 
commonly observed for proteins with significant acidic residue content (Asp and Glu), which 
affects binding of SDS to the protein.43-44 Both Alkbh5 and FTO have a relatively high number of 
acidic residues (~15% and ~16%, respectively). Complementary analysis of our purified 
samples by liquid chromatography with tandem mass spectrometry (LC-MS/MS) returns masses 
of 26,374 Da and 54,809 Da for Alkbh5 and FTO, respectively, confirming that the purified 
proteins are the truncated constructs of the two RNA demethylases. Favorably, the purified 
Alkbh5 and FTO remain soluble at room temperature and relatively high concentration (~0.5 
mM) for several weeks under various buffer conditions (tested at pH 6.5, 7.4, and 8.0, NaCl 
concentrations of 0 mM, 100 mM, and 200 mM, and MnCl2 concentrations of 0 mM, 1 mM, and 
2 mM). 
To test whether the EIN tag promoted correct folding we have developped a Liquid 
Chromatography–Mass Spectrometry (LC-MS) method to monitor the demethylation of the 5-
mer substrate, 5’-GG(m6A)CT-3’, catalyzed by Alkbh5 and FTO. Briefly, various concentrations 
of substrate were incubated with 0.1 µM Alkbh5 or 2 µM FTO at 37 °C. At regular intervals, 50 
µL aliquots were mixed with a 1:1 ratio of 20% (v/v) formic acid to quench the reaction for 
subsequent analysis by LC-MS (see Materials and Methods). Results indicate the presence of 
two peaks in the LC dimension, which correspond to the methylated and demethylated 
nucleotides, as confirmed by the molecular masses deconvoluted from the MS dimension of the 
experiment (Figure 3b). Initial velocities (v0) at different substrate concentrations were obtained 
from analyzing plots of the concentration of demethylated nucleotide (calculated from the 
integrated areas of the LC peaks) versus time (Figure 3c) and used to fit the Michaelis-Menten 
parameters for the demethylation reactions catalyzed by Alkbh5 and FTO (Figure 3d). Km values 
of 1.6 µM and 12.6 µM, and kcat values of 2.6 min
-1 and 0.02 min-1 were obtained for Alkbh5 and 
FTO, respectively, which are consistent with the slow reaction kinetics previously reported for 
these enzymes.21 
Comparison between MBP and EIN solubility tags – We also compared the overall performance 
of the MBP and EIN solubility tags for recombinant expression of Alkbh5 and FTO in M9 
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minimal medium. The use of the MBP tag resulted in production of ~5 mg/L of purified Alkbh5 
and ~11 mg/L of purified FTO, while the use of the EIN tag resulted in production of ~12 mg/L of 
purified Alkbh5 and ~20 mg/L of purified FTO, indicating that EIN is better suited for 
recombinant expression of the human RNA demethylases in E. coli. Interestingly, EIN is cleaved 
off the target protein more efficiently than MBP upon digestion with TEV protease. Indeed, near-
complete removal of EIN from the fusion partner is obtained in less than 4 hours, while MBP 
requires overnight incubation with the protease to reach a sufficient level of cleavage (Figure 4). 
The more efficient cleavage of EIN from the target protein results in faster purification protocols, 
therefore reducing the risk of misfolding and sample degradation via proteolysis.45  
 
Conclusion 
In this contribution, we have presented protocols for recombinant expression and purification of 
the human RNA demethylases Alkbh5 and FTO. We have used a fusion partner to increase the 
solubility of the target enzymes and maximize the overall yield, required for structural and 
biochemical studies of these proteins. Our data indicate that (i) the N-terminal domain of 
bacterial enzyme I (EIN) is slightly more efficient than MBP at facilitating expression of soluble 
Alkbh5 and FTO in E. coli (see Comparison between MBP and EIN solubility tags in the Results 
section), and (ii) EIN is cleaved off the target enzyme considerably faster than MBP (Figure 4), 
therefore minimizing both the purification time and the risk for proteolytic cleavage from 
endogenous proteases. Furthemore, while the EIN tag was essential to afford high protein 
solubility in E. coli, the purified proteins retained high solubility after cleavage, indicating that the 
EIN does not stabilize Alkbh5 and FTO folds via tight interactions. We have shown that the 
purified proteins are enzymatically active, which permits detailed structural and functional 
studies on the interactions between the RNA demethylases and their physiological substrates. 
To the best of our knowledge, the use of EIN as an efficient solubility tag has not been 
previously reported yet. Our work demonstrates that EIN can be added to the catalog of the 
available fusion partners for protein production and purification in bacterial hosts. The plasmid 
used here to express Alkbh5 fused to the N-terminal EIN-tag (Figure 2) has been deposited on 
Addgene (plasmid # 125732). 
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Figure Legends 
Figure 1. Expression of Alkbh5 in (a) LB and (c) M9 medium, respectively. Expression of FTO 
in (b) LB and (d) M9 medium, respectively. Lane 1 is the molecular weight marker; lanes 2 and 
3 correspond to the insoluble and soluble fractions of the target protein, respectively; lanes 4 
and 5 correspond to the insoluble and soluble fractions of the MBP-target protein fusion 
construct, respectively; lanes 6 and 7 correspond to the insoluble and soluble fractions of the 
EIN-target protein fusion construct, respectively. Inclusion bodies were harvested by 
centrifugation of 20 mL of cell lysate and resuspended in 20 mL of 8 M urea. 10 µL of 
centrifuged cell lysate (soluble fraction) and 10 µL of resuspended inclusion bodies (insoluble 
fraction) were mixed with 10 µL of 2X SDS loading buffer, heated at 90 °C for 10 min and 
analyzed on 4-12% Bis-Tris SDS-PAGE gels. The bands on the SDS-PAGE gel relative to the 
relevant proteins are highlighted using red rectangles and were quantified using the 
densitometry functions of ImageJ software46. Measured intensities are reported in the top panel. 
 
Figure 2. (a) Map of the plasmid used for expression of Alkbh5 and FTO with an N-terminal 
fusion tag. A gene encoding a ribosome binding site (RBS), a N-terminal His-tag, the EIN or 
MBP solubility tag, a TEV recognition site, an Nde I restriction site, and the target protein was 
cloned between the Xba I and BamH I sites of a pET21a vector. The size of the vectors 
incorporating the MBP and EIN fusion partners are 6,588 bp and 6,222 bp, respectively. The 
Alkbh5 and FTO nucleotide sequences are 681 and 1,422 bp, respectively. Details about the 
cloning/expression region are shown in (b). The nucleotide sequence of the EIN-fusion 
construct is reported as Supporting Information. 
 
Figure 3. (a) SDS-PAGE analysis of purified Alkbh5 (lane 2) and FTO (lane 3). The molecular 
weight marker is shown in lane 1. (b) Example of extracted LC-MS data measured for the m6A 
demethylation reaction catalyzed by FTO. The LC dimension (left panel) shows two well 
resolved signals (colored blue and orange, respectively). The MS dimension of the experiment 
(right panel) reveals that the blue and orange peaks correspond to the -2 ionized species of the 
demethylated and methylated nucleotide, respectively. The smaller peaks observed in the MS 
dimension correspond to Na+ adducts. (c) Plot of the concentration of demethylated nucleotide 
versus time measured for the demethylation reaction catalyzed by FTO at three different 
concentrations of substrate (4 µM, green; 12 µM, orange; 20 µM, blue). The slope of the linear 
14 
 
portion of the plot (solid line) has been fit to determine the initial velocity of the reaction (v0). (d) 
Michaelis-Menten plot for the demethylation reaction catalyzed by 0.1 µM Alkbh5 (left panel) 
and 2.0 µM FTO (right panel). 
Figure 4. Time dependence for the cleavage of the fusion constructs catalyzed by 15 µg/mL 
TEV at 25 °C. (a) MBP-Alkbh5, (b) EIN-Alkbh5, (c) MBP-FTO, and (d) EIN-FTO. The bands 
highlighted by the red boxes were quantified using the densitometry functions of ImageJ 
software 46. Measured intensities are reported in the top panels. 
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Highlights 
 
• Overexpression of Alkbh5 and/or FTO links to leukemia, breast, and brain cancer 
 
• The EIN domain of Enzyme I is an efficient solubility tag for recombinant 
expression 
 
• EIN is cleaved off the target protein more efficiently than MBP 
 
• EIN allows recombinant expression of mg amounts of Alkbh5 and FTO in LB and 
M9 media 
 
 
 
